Family Planning: The Responsibility to Prevent Both Pregnancy and Reproductive Tract Infections

  • Willard Cates
  • Katherine M. Stone
Part of the Reproductive Biology book series (RBIO)

Abstract

Using contraception has two main benefits: prevention of unplanned pregnancy and protection against reproductive tract infections (RTIs).1–4 But technology development, policy emphasis, and service delivery have focused almost solely on preventing pregnancy, with little attention paid to reducing RTIs. Abstinence from sexual intercourse provides nearly absolute protection against both outcomes. For those choosing to be sexually active, contraception reduces, but does not eliminate, the risk of either pregnancy or RTIs. Unfortunately, the contraceptives with the best record for pregnancy prevention provide minimal RTI protection. Some contraceptives may even raise the risk of certain infections. Thus, decisions about contraception by individuals, communities, and policymakers should involve balancing the relative need to prevent both RTIs and unplanned pregnancy.

Keywords

Human Immunodeficiency Virus Family Planning Human Immunodeficiency Virus Infection Bacterial Vaginosis Chlamydia Trachomatis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Grimes DA, Cates W, Jr. Family planning and sexually transmitted diseases. In: Holmes KK, Mârdh P-A, Sparling PF et al., eds. Sexually transmitted diseases, second edition, New York: McGraw-Hill, 1990: 1087–94.Google Scholar
  2. 2.
    Harlap S, Kost K, Forrest JD. Preventing pregnancy, protecting health: a new look at birth control choices in the United States, New York: The Alan Guttmacher Institute, 1991.Google Scholar
  3. 3.
    DaVanzo J, Parnell AM, Foege WH. Health consequences of contraceptive use and reproductive patterns. JAMA 1991; 265: 2692–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Cates W Jr. Sexually transmitted diseases and family planning. Strange or natural bedfellows? J Reprod Med 1984; 29: 317–22.Google Scholar
  5. 5.
    Luker K. Contraceptive risk taking and abortion. Stud Fam Plann 1977; 8: 190–6.PubMedCrossRefGoogle Scholar
  6. 6.
    Horowitz DR, Oechsli W. Contraceptive risk-taking in a population with limited access to abortion. J Biosoc Sci 1980; 12: 373–82.PubMedCrossRefGoogle Scholar
  7. 7.
    Hatcher RA, Stewart FA, Trussell TJ, et al., eds. Contraceptive Technology, 1990–1992, 15th edition, New York: Irvington Press, 1990.Google Scholar
  8. 8.
    Hearst N, Hulley SB. Preventing the heterosexual spread of AIDS: are we giving our patients the best advice? JAMA 1988; 259: 2428–32.PubMedCrossRefGoogle Scholar
  9. 9.
    May RM, Anderson RM. Transmission dynamics of HIV infection. Nature 1987; 326: 137–42.PubMedCrossRefGoogle Scholar
  10. 10.
    Caldwell JC, Caldwell P. The cultural context of high fertility in Sub-Saharan Africa. Popul Develop Rev 1987; 13: 409–37.CrossRefGoogle Scholar
  11. 11.
    Caldwell JC, Caldwell P, Quiggin P. The social context of AIDS in Sub-Saharan Africa. Popul Develop Rev 1989; 15: 185–234.CrossRefGoogle Scholar
  12. 12.
    Fineberg HB. Education to prevent AIDS: prospects and obstacles. Science 1988; 239: 592–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Eisenberg B. The number of partners and the probability of HIV infection. Statistics Med 1989; 8: 83–92.CrossRefGoogle Scholar
  14. 14.
    Reiss IL, Leik RK. Evaluating strategies to avoid AIDS: number of partners versus use of condoms. J Sex Res 1989; 26: 411–33.CrossRefGoogle Scholar
  15. 15.
    Cates W Jr, Rolfs RT Jr, Aral SO. Sexually transmitted diseases, pelvic inflammatory disease and infertility: an epidemiologic update. Epidemiol Rev 1990; 12: 199–220.PubMedGoogle Scholar
  16. 16.
    Widdus R, Meheus A, Short R. The management of risk in sexually transmitted diseases. Daedalus 1990; 119: 177–91.Google Scholar
  17. 17.
    Aral SO, Guinan ME. Women and sexually transmitted diseases. In: Holmes KK, Mârdh P-A, Sparling PF, Wiesner PJ, eds. Sexually transmitted diseases, first edition, New York: McGraw-Hill, 1984: 85–9.Google Scholar
  18. 18.
    Sobel JD. Vaginal infections in adult women. Med Clin N Amer 1990; 74: 1573–1602.PubMedGoogle Scholar
  19. 19.
    Rolfs RT, Galaid EI, Zaidi AA. Pelvic inflammatory disease: trends in hospitalizations and office visits, 1979–1988. Submitted for publication, 1991.Google Scholar
  20. 20.
    Drotman DP. Epidemiology and treatment of epididymitis. Rev Infect Dis 1982; Suppl 4: S788–93.Google Scholar
  21. 21.
    Krieger JN. Prostatitis syndromes: pathophysiology, differential diagnosis, and treatment. Sex Transm Dis 1984; 11: 100–12.PubMedCrossRefGoogle Scholar
  22. 22.
    Larson A. Social context of human immunodeficiency virus transmission in Africa: historical and cultural bases of East and Central African sexual relations. Rev Infect Dis 1989; 11: 716–24.PubMedCrossRefGoogle Scholar
  23. 23.
    Cates W Jr. The epidemiology and control of sexually transmitted diseases in adolescents. In: Schydlower M, Shafer M-A, eds. AIDS and the other sexually transmitted diseases. Adolesc Med State Art Rev 1990; 3: 409–27.Google Scholar
  24. 24.
    Henshaw SK, Van Vort J. Abortion services in the United States, 1987 and 1988. Fam Plann Perspect 1990; 22: 102–9.PubMedCrossRefGoogle Scholar
  25. 25.
    Aral SO, Holmes KK. Epidemiology of sexual behavior and sexually transmitted diseases. In: Holmes KK, Mârdh P-A, Sparling PF et al., eds. Sexually transmitted diseases, second edition, New York: McGraw-Hill, 1990: 19–36.Google Scholar
  26. 26.
    Johnson RE, Nahmias AJ, Magder LS, Lee FK, Brooks CA, Snowden CB. A seroepidemiologic survey of the prevalence of herpes simplex virus type 2 infection in the United States. N Engl J Med 1989; 321: 7–12.PubMedCrossRefGoogle Scholar
  27. 27.
    Mosher WD. Fecundity and infertility in the United States. Am J Public Health 1988; 78: 181–2.PubMedCrossRefGoogle Scholar
  28. 28.
    Platt R, Rice PA, McCormack WM. Risk of acquiring gonorrhea and prevalence of abnormal adnexal findings among women recently exposed to gonorrhea. JAMA 1983; 250: 3205–9.PubMedCrossRefGoogle Scholar
  29. 29.
    Hooper RR, Reynolds GH, Jones OG et al. Cohort study of venereal disease. I. The risk of gonorrhea transmission from infected women to men. Am J Epidemiol 1978; 108: 136–44.PubMedGoogle Scholar
  30. 30.
    Brunham RC, Plummer FA. A general model of sexually transmitted disease epidemiology and its implications for control. Med Clin N Amer 1990; 74: 1339–52.PubMedGoogle Scholar
  31. 31.
    Trussell J, Kost K. Contraceptive failure in the United States: a critical review of the literature. Stud Fam Plann 1987; 18: 237–83.PubMedCrossRefGoogle Scholar
  32. 32.
    CDC. Number of sex partners and potential risk of sexual exposure to human immunodeficiency virus. MMWR 1988; 37: 565–8.Google Scholar
  33. 33.
    Mastroianni L Jr, Donaldson PJ, Kane TT. Development of contraceptives-obstacles and opportunities. N Engl J Med 1990; 322: 482–4.PubMedCrossRefGoogle Scholar
  34. 34.
    Peterson HB, Galaid EI, Zenilman JM. Pelvic inflammatory disease: review of treatment options. Rev Infect Dis 1990; 12 (Suppl 6): S656–64.PubMedCrossRefGoogle Scholar
  35. 35.
    Department of Health and Human Services, Office of Population Affairs. Guidelines for clinical practice for facilities funded under Title X, Washington, DC, 1989.Google Scholar
  36. 36.
    Parra W, Drotman DP, Siegel K, Esteves K, Baker T. Patient counseling and behavior modification. In: Holmes KK, Mârdh P-A, Sparling PF et al., eds. Sexually transmitted diseases, second edition, New York: McGraw-Hill, 1990: 1057–68.Google Scholar
  37. 37.
    Forrest JD. The delivery of family planning services in the United States. Fam Plann Perspect 1988; 20: 88–98.CrossRefGoogle Scholar
  38. 38.
    Bennett FJ. Control of sexually transmitted diseases in the tropics and developing countries. In: Osaba AO, ed. Sexually transmitted diseases in the tropics, London: Baillière-Tyndal, 1987: 223–44.Google Scholar
  39. 39.
    Wasserheit JN. Reproductive tract infections. Presented at 117th Annual Meeting of the American Public Health Association, Chicago, October 17, 1989.Google Scholar
  40. 40.
    Stone KM, Grimes DA, Magder LS. Personal protection against sexually transmitted diseases. Am J Obstet Gynecol 1986; 155: 180–8.PubMedGoogle Scholar
  41. 41.
    Stone KM, Grimes DA, Magder LS. Primary prevention of sexually transmitted diseases: a primer for clinicians. JAMA 1986; 255: 1763–6.PubMedCrossRefGoogle Scholar
  42. 42.
    McGregor JA, French JI, Spencer NE. Prevention of sexually transmitted diseases in women. J Reprod Med 1988; 33: 109–18.PubMedGoogle Scholar
  43. 43.
    Feldblum PJ, Fortney JA. Condoms, spermicides, and the transmission of human immunodeficiency virus: a review of the literature. Am J Public Health 1988; 78: 52–4.PubMedCrossRefGoogle Scholar
  44. 44.
    Cates W Jr. STDs and contraceptive choice. Outlook 1988; 6 (2): 2–6.Google Scholar
  45. 45.
    North BB. Effectiveness of vaginal contraceptives in prevention of sexually transmitted diseases. In: Alexander NJ, Gabelnick HL, Spieler JM, eds. Heterosexual transmission of AIDS, New York: Wiley-Liss, 1990: 273–88.Google Scholar
  46. 46.
    Stone KM. Avoiding sexually transmitted diseases. Obstet Gynecol Clin N America 1990; 17: 789–99.Google Scholar
  47. 47.
    Hulley SB, Newman TB, Cummings SR. Getting started: the anatomy and physiology of research. In: Hulley SB, Cummings RB, eds. Designing clinical research, Baltimore: Williams and Wilkins, 1988: 1–11.Google Scholar
  48. 48.
    Liskin L, Wharton C, Blackburn R et al. Condoms: the challenge. Popul Rep 1990; H-8.Google Scholar
  49. 49.
    CDC. Condoms for prevention of sexually transmitted diseases. MMWR 1988; 37: 133–7.Google Scholar
  50. 50.
    Judson FN, Ehret JM, Bodin GF, Levin MJ, Rietjmeijer CAM. In vitro evaluation of condoms with and without nonoxynol-9 as physical and chemical barriers against Chlamydia trachomatis, herpes simplex virus type 2 and human immunodeficiency virus. Sex Transm Dis 1989; 16: 51–6.PubMedCrossRefGoogle Scholar
  51. 51.
    Conant MA, Spicer DW, Smith CD. Herpes simplex virus transmission. Sex Transm Dis 1984; 11: 94–5.PubMedCrossRefGoogle Scholar
  52. 52.
    Katznelson S, Drew WL, Mintz L. Efficacy of the condom as a barrier to the transmission of cytomegalovirus. J Infect Dis 1984; 150: 155–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Conant M, Hardy D, Sematinger J, Spicer D, Levy JA. Condoms prevent transmission of AIDS-associated retrovirus. JAMA 1986; 255: 1706.PubMedCrossRefGoogle Scholar
  54. 54.
    Minuk GY, Bohme CE, Bowen TJ. Condoms and hepatitis B virus infection. Ann Intern Med 1986; 104: 584.PubMedCrossRefGoogle Scholar
  55. 55.
    Minuk GY, Bohme CE, Bowen TJ, Cassol S. Condoms and prevention of AIDS. JAMA 1986; 256: 1443.CrossRefGoogle Scholar
  56. 56.
    Van de Perre P, Jacobs D, Sprecher-Goldberger S. The latex condom, an efficient barrier against sexual transmission of AIDS-related viruses. AIDS 1987; 1: 49–52.PubMedGoogle Scholar
  57. 57.
    Lytle CD, Carney PG, Vohra S et al. Virus leakage through natural membrane condoms. Fifth International Conference on AIDS, Abstract No. M.A.P. 114, Montreal, June 4–9, 1989.Google Scholar
  58. 58.
    Pemberton J, McCann JS, Mahony DH, MacKenzie G, Dougan I, Hay I. Socio-medical characteristics of patients attending a VD clinic and the circumstances of infection. Br J Vener Dis 1972; 48: 391–6.PubMedGoogle Scholar
  59. 59.
    McCormack WM, Lee Y, Zinner SH. Sexual experience and urethral colonization with genital mycoplasmas: a study in normal men. Ann Intern Med 1973; 78: 696–8.PubMedCrossRefGoogle Scholar
  60. 60.
    Barlow D. The condom and gonorrhoea. Lancet 1977; 2: 811–12.PubMedCrossRefGoogle Scholar
  61. 61.
    Hart G. Factors influencing venereal infection in a war environment. Br J Vener Dis 1974; 50: 68–72.PubMedGoogle Scholar
  62. 62.
    Darrow WW. Condom use and use-effectiveness in high-risk populations. Sex Transm Dis 1989; 16: 157–60.PubMedCrossRefGoogle Scholar
  63. 63.
    Oberle MW, Rosero-Bixby L, Lee FK, Sanchez-Braverman M, Nahmias AJ, Guinan ME. Herpes simplex virus type 2 antibodies: high prevalence in monogamous women in Costa Rica. Am J Trop Med Hygiene 1989; 41: 224–9.Google Scholar
  64. 64.
    Austin H, Louv WC, Alexander WJ. A case-control study of spermicides and gonorrhea. JAMA 1984; 251: 2822–4.PubMedCrossRefGoogle Scholar
  65. 65.
    Syrjanen K, Vayrynen M, Catren O et al. Sexual behavior of women with human papilloma virus (HPV) lesions of the uterine cervix. Br J Vener Dis 1984; 60: 243–8.PubMedGoogle Scholar
  66. 66.
    Rosenberg MJ, Davidson AJ, Chen J-H, Douglas JM, Judson FN. Comparative effects of barrier contraceptives on sexually transmitted diseases in women. Submitted for publication, 1991.Google Scholar
  67. 67.
    Kelaghan J, Rubin GL, Ory HW, Layde PM. Barrier-method contraceptives and pelvic inflammatory disease. JAMA 1982; 248: 184–7.PubMedCrossRefGoogle Scholar
  68. 68.
    Cramer DW, Goldman MB, Schiff I et al. The relationship of tubal infertility to barrier method and oral contraceptive use. JAMA 1987; 257: 2446–50.PubMedCrossRefGoogle Scholar
  69. 69.
    Mann J, Quinn TC, Piot P et al. Condom use and HIV infection among prostitutes in Zaire. N Engl J Med 1987; 316: 345.PubMedGoogle Scholar
  70. 70.
    Padian N. Male-to-female transmission of human immunodeficiency virus. JAMA 1987; 258: 3386–7.CrossRefGoogle Scholar
  71. 71.
    Quinn TC, Glasser D, Cannon RO et al. Human immunodeficiency virus infection among patients attending clinics for sexually transmitted diseases. N Engl J Med 1988; 318: 197–203.PubMedCrossRefGoogle Scholar
  72. 72.
    Smiley ML, White GC, Becherer P et al. Transmission of human immunodeficiency virus to sexual partners of hemophiliacs. Am J Hematol 1988; 28: 27–32.PubMedCrossRefGoogle Scholar
  73. 73.
    Roumelioutou-Karayannis A, Nestoridou K, Mandalaki T et al. Heterosexual transmission of HIV in Greece. AIDS Res Hum Retroviruses 1988; 4: 233–6.PubMedCrossRefGoogle Scholar
  74. 74.
    Fischl MA, Dickinson GM, Scott GB, Limas N, Fletcher MA, Parks W. Evaluation of heterosexual partners, children, and household contacts of adults with AIDS. JAMA 1987; 257: 6404.Google Scholar
  75. 75.
    Ngugi EN, Plummer FA, Simonsen JN et al. Prevention of transmission of human immunodeficiency virus in Africa: effectiveness of condom promotion and health education among prostitutes. Lancet 1988; 2: 887–90.PubMedCrossRefGoogle Scholar
  76. 76.
    Laurian Y, Peynet J, Verroust F. HIV infection in sexual partners of HIV seropositive patients with hemophilia. N Engl J Med 1989; 320: 183.PubMedGoogle Scholar
  77. 77.
    Kamenga M, Ryder RW, Jingu M et al. Evidence of marked sexual behavior change associated with low HIV-1 seroconversion in 149 married couples with discordant HIV-1 serostatus: experience in an HIV counseling center in Zaire. AIDS 1991; 5: 61–7.PubMedCrossRefGoogle Scholar
  78. 78.
    Allen S, Lindan CP, Hulley S, Carael M, Black D, Coates T. Behavior change among HIV- and HIV+ urban Rwandan women. Presented at National Institute of Mental Health Workshop on HIV Prevention and Behavior Change, Washington, DC, April 4, 1991.Google Scholar
  79. 79.
    Trussell J, Menken J. Lifetable analysis of contraceptive failure. In: Hermalin AI, Entwisle B, eds. The role of surveys in the analysis of family planning programs, Liège: Ordina Editions, 1982: 537–71.Google Scholar
  80. 80.
    Trussell J. Hatcher RA, Cates W Jr, Stewart FH, Kost K. Contraceptive failure in the United States: an update. Stud Fam Plann 1990; 21: 51–4.PubMedCrossRefGoogle Scholar
  81. 81.
    Nakamura RM, Coulson AH, Voeller R et al. In vitro condom testing [Abstract 6510]. In: Program and abstracts, IV international conference on AIDS, Stockholm: Stockholm International Fairs, 1988.Google Scholar
  82. 82.
    Free MJ, Hutchings J. Condom quality management. In: Alexander NJ, Gabelnick HL, Spieler JM, eds. Heterosexual transmission of AIDS, New York: Wiley-Liss, 1990: 370–97.Google Scholar
  83. 83.
    Vessey MP, Villard-Mackintosh L, McPherson K, Yeates D. Factors influencing use-effectiveness of the condom. Br J Fam Plann 1988; 14: 40–3.Google Scholar
  84. 84.
    Consumers Union. Can you rely on condoms? Consumer Rep 1989; (March): 135–41.Google Scholar
  85. 85.
    Golombok S, Sketchly J, Rust J. Condom failure among homosexual men. J AIDS 1989; 2: 404–9.Google Scholar
  86. 86.
    Tindall B, Swanson C, Donovan B, Cooper DA. Sexual practices and condom usage in a cohort of homosexual men in relation to human immmunodeficiency virus status. Med J Aust 1989; 151: 318–22.PubMedGoogle Scholar
  87. 87.
    vanGriensven GJP, deVroome EMM, Tielman RAP, Coutinho RA. Failure rate of condoms during anogenital intercourse in homosexual men. Genitourin Med 1988; 64: 344–6.Google Scholar
  88. 88.
    Albert AE, Hatcher RA, Graves W. Condom use and breakage among women in a municipal hospital family planning clinic. Contraception 1991; 43: 167–76.PubMedCrossRefGoogle Scholar
  89. 89.
    Richters J, Donovan B, Gerofi J, Watson L. Low condom breakage rate in commercial sex. Lancet 1988; 2: 1489.Google Scholar
  90. 90.
    Program for Appropriate Technology in Health, Program for Introduction and Adaptation of Contraceptive Technology. Monitoring condom quality. Outlook 1987; 5: 2–5.Google Scholar
  91. 91.
    Ahmed G, Liner EC, Williamson NE, Schellstede WP. Characteristics of condom use and associated problems: experience in Bangladesh. Contracept 1990; 42: 523–33.CrossRefGoogle Scholar
  92. 92.
    Wright EA, Kapu MM, Wada I. Use of condoms as contraceptive and disease preventive measures among residents of Jos, northern Nigeria. Contracept 1990; 42: 621–7.CrossRefGoogle Scholar
  93. 93.
    Potter LS, Clarke K. Multicountry study of acceptability of spermicidally lubricated condoms: summary report, volume 1. Research Triangle Park, NC: Family Health International, 1988. Unpublished.Google Scholar
  94. 94.
    Population Council. Study of the determinants and quality of condom use in two eastern Caribbean countries: Barbados and St. Lucia. Final technical report, New York, 1990.Google Scholar
  95. 95.
    Piedrahita C, Hinson K, Foldesy R, Steiner M, Joanis C. Latex condom breakage study, Barbados and St. Lucia condom lot. Research Triangle Park, NC: Family Health International, 1990. Unpublished.Google Scholar
  96. 96.
    Drew WL, Blair M, Miner RC, Conant M. Evaluation of the virus permeability of a new condom for women. Sex Transm Dis 1990; 17: 110–2.PubMedCrossRefGoogle Scholar
  97. 97.
    Singh B, Cutler JC, Utdjiam HMD. Studies on the development of a vaginal preparation providing both prophylaxis against venereal disease and other genital infections and contraception. Br J Vener Dis 1972; 48: 57–64.PubMedGoogle Scholar
  98. 98.
    Bolch OH Jr, Warren JC. In vitro effects of Emko on Neisseria gonorrhoeae and Trichomonas vaginalis. Am J Obstet Gynecol 1973; 115: 1145–8.PubMedGoogle Scholar
  99. 99.
    Cowan ME, Cree GE. A note on the susceptibility of N. gonorrhoeae to contraceptive agent Nonyl-P. Br J Vener Dis 1973; 49: 65–6.Google Scholar
  100. 100.
    Singh B, Postic B, Cutler JC. Virucidal effect of certain chemical contraceptives on type 2 herpes virus. Am J Obstet Gynecol 1976; 126: 422–5.PubMedGoogle Scholar
  101. 101.
    Asculai SS, Weis MT, Rancourt MW, Kupfenberg AB. Inactivation of herpes simplex viruses by nonionic surfactants. Antimicrob Agents Chemother 1978; 13: 686–90.PubMedCrossRefGoogle Scholar
  102. 102.
    Hicks DR, Martin LS, Getchell JP et al. Inactivation of HTLV-III/LAV-infected cultures of normal human lymphocytes in vitro. Lancet 1985; 2: 1422–3.PubMedCrossRefGoogle Scholar
  103. 103.
    Amortegui AJ, Melder RJ, Meyer MP, Singh B. The effect of chemical intravaginal contraceptives and betadine on Ureaplasma urealyticum. Contracept 1984; 30: 135–41.CrossRefGoogle Scholar
  104. 104.
    Benes S, McCormack WM. Inhibition of growth of Chlamydia trachomatis by nonoxynol-9 in vitro. Antimicrob Agents Chemother 1985; 27: 724–6.PubMedCrossRefGoogle Scholar
  105. 105.
    Kelly JP, Reynolds RB, Stagno S, Louv WC, Alexander WJ. In vitro activity of the spermicide nonoxynol-9 against Chlamydia trachomatis. Antimicrob Agents Chemother 1985; 27: 60–2.CrossRefGoogle Scholar
  106. 106.
    Amortegui AJ, Myer MP. The in vitro effect of chemical intravaginal contraceptives on Chlamydia trachomatis. Contracept 1987; 36: 481–85.CrossRefGoogle Scholar
  107. 107.
    Kappus EW, Quinn TC. The spermicide nonoxynol-9 does not inhibit Chlamydia trachomatis in vitro. Sex Transm Dis 1986; 13: 134–7.PubMedCrossRefGoogle Scholar
  108. 108.
    Quinn TW, O’Reilly KR. Contraceptive practices of women attending the sexually transmitted disease clinic in Nashville, Tennessee. Sex Transm Dis 1985; 12: 99–102.PubMedCrossRefGoogle Scholar
  109. 109.
    Cole CH, Lacher TG, Bailey JC, Fairclough DL. Vaginal chemoprophylaxis in the reduction of reinfection of women with gonorrhoeae. Br J Vener Dis 1980; 56: 314–18.PubMedGoogle Scholar
  110. 110.
    Jick H, Hannan MR, Stergachis A, Heidrich F, Perera DR. Vaginal spermicides and gonorrhea. JAMA 1982; 248: 1619–21.PubMedCrossRefGoogle Scholar
  111. 111.
    Louv WC, Austin H, Alexander WJ, Stagno S, Cheeks J. A clinical trial of nonoxynol-9 as a prophylaxis for cervical Neisseria gonorrhoeae and Chlamydia trachomatis infections. J Infect Dis 1988; 158: 518–23.PubMedCrossRefGoogle Scholar
  112. 112.
    Cutler JC, Singh B, Carpenter U. Vaginal contraceptives as prophylaxis against gonorrhea and other sexually transmissible diseases. Adv Planned Parent 1977; 12: 45–56.Google Scholar
  113. 113.
    Rendon AL, Covarrubias J, McCamey KE, Marion-Landais G, Luna del Villar J. A controlled, comparative study of phenylmercuric acetate, nonoxynol-9 and placebo vaginal suppositories as prophylactic agents against gonorrhea. Curr Ther Res 1980; 27: 780–3.Google Scholar
  114. 114.
    Berger GS, Keith L, Moss W. Prevalence of gonorrhea among women using various methods of contraception. Br J Vener Dis 1975; 51: 307–9.PubMedGoogle Scholar
  115. 115.
    Magder LS, Harrison HR, Ehret JM, Anderson TS, Judson FN. Factors related to genital Chlamydia trachomatis and its diagnosis by culture in a sexually transmitted disease clinic. Am J Epidemiol 1988; 28: 298–308.Google Scholar
  116. 116.
    Rosenberg MJ, Rojanapithayakom W, Feldblum PJ, Higgins JE. Effect of the contraceptive sponge on chlamydial infection, gonorrhea, and candidiasis. A comparative clinical trial. JAMA 1987; 257: 2308–12.PubMedCrossRefGoogle Scholar
  117. 117.
    Kjaer SK, Engholm G, Teisen C et al. Risk factors for cervical human papilloma virus and herpes simplex virus infections in Greenland and Denmark: a population-based study. Am J Epidemiol 1990; 131: 669–82.PubMedGoogle Scholar
  118. 118.
    Hooton RM, Hillier S, Johnson C, Roberts PL, Stamm WE. Escherichia coli bacteriuria and contraceptive method. JAMA 1991; 265: 64–9.PubMedCrossRefGoogle Scholar
  119. 119.
    Eschenbach DA, Hillier S, Critchlow C et al. Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 1988; 158: 819–28.PubMedGoogle Scholar
  120. 120.
    Kreiss J, Ruminjo I, Ngugi E, Roberts P, Ndinya-Achola J, Plummer F. Efficacy of nonoxynol-9 in preventing HIV transmission. F.fth International Conference on AIDS, Abstract No. MAO 361, Montreal, June 5, 1989.Google Scholar
  121. 121.
    Reckart ML, Barnett JA, Manzon LM, Wittenberg L, McNabb A. Nonoxynol-9: its adverse effects. Sixth International Conference on AIDS, Abstract No. SC 36, San Francisco, June 23, 1990.Google Scholar
  122. 122.
    Trap R, Trap B, Peterson CS. Evaluation of the amount of nonoxynol-9 available in condoms for the inhibition of HIV using a method based on HPLC. Int J STD AIDS 1990; 1: 346–8.PubMedGoogle Scholar
  123. 123.
    Washington AE, Gove S, Schachter J, Sweet RL. Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease. JAMA 1985; 253: 2246–50.PubMedCrossRefGoogle Scholar
  124. 124.
    McCormack WM, Rosner B, McComb DE et al. Infection with Chlamydia trachomatis in female college students. Am J Epidemiol 1985; 121: 107–15.PubMedGoogle Scholar
  125. 125.
    Handsfield HH, Jasman LL, Robert PL et al. Criteria for selective screening for Chlamydial trachomatis infection in women attending family planning clinics. JAMA 1986; 255: 1730–34.PubMedCrossRefGoogle Scholar
  126. 126.
    Avonts D, Sercu M, Heyerick P, Vandermeeren I, Meheus A, Piot P. Incidence of uncomplicated genital infections in women using oral contraception or an intrauterine device: a prospective study. Sex Transm Dis 1990; 17: 23–29.PubMedGoogle Scholar
  127. 127.
    Harrison HR, Costin M, Meder JB et al. Cervical Chlamydia trachomatis infection in university women: relationship to history, contraception, ectopy, and cervicitis. Am J Obstet Gynecol 1985; 153: 244–51.PubMedGoogle Scholar
  128. 128.
    Weström L. Incidence, prevalence, and trends of acute pelvic inflammatory disease and its consequences in industrialized countries. Am J Obstet Gynecol 1980; 138: 880–92.PubMedGoogle Scholar
  129. 129.
    Eschenbach DA, Hamish JP, Holmes KK. Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol 1977; 128: 838–50.PubMedGoogle Scholar
  130. 130.
    Royal College of General Practitioners Oral Contraception Study. Oral contraceptives and health, New York: Pitman, 1974.Google Scholar
  131. 131.
    Panser LA, Phipps WR. Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 1991; 93: 91–9.CrossRefGoogle Scholar
  132. 132.
    Rubin GL, Ory HW, Layde PM. Oral contraceptives and pelvic inflammatory disease. Am J Obstet Gynecol 1982; 144: 630–5.PubMedGoogle Scholar
  133. 133.
    Wolner-Hanssen P, Svensson L, Mardh P-A, Weström L. Laparoscopic findings and contraceptive use in women with signs and symptoms suggestive of acute salpingitis. Obstet Gynecol 1985; 66: 233–8.PubMedGoogle Scholar
  134. 134.
    Wolner-Hanssen P, Eschenbach DA, Paavonen J et al. Decreased risk of symptomatic chlamydial pelvic inflammatory disease associated with oral contraceptive use. JAMA 1990; 263: 54–9.PubMedCrossRefGoogle Scholar
  135. 135.
    Wolner-Hanssen P. Oral contraceptive use modifies the manifestations of pelvic inflammatory disease. Br J Obstet Gynaecol 1986; 93: 619–24.PubMedCrossRefGoogle Scholar
  136. 136.
    Svensson L, Weström L, Mârdh P-A. Contraceptives and acute salpingitis. JAMA 1984; 251: 2553–5.PubMedCrossRefGoogle Scholar
  137. 137.
    Grossman C. Possible underlying mechanisms of sexual dimorphism in the immune response, fact and hypothesis. J Steroid Biochem 1989; 34: 241–51.PubMedCrossRefGoogle Scholar
  138. 138.
    Hunter DJ, Mati JK. Contraception, family planning, and HIV. Presented at the International Workshop on AIDS and Reproductive Health, Bellagio, Italy, October 1990. To be published by Plenum Press in AIDS and Women’s Health.Google Scholar
  139. 139.
    Plummer FA, Simonsen JN, Cameron DW et al. Cofactors in male-female sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991; 163: 233–39.PubMedCrossRefGoogle Scholar
  140. 140.
    Hira SK, Kamanga J, Macuacua R, Feldblum PJ. Oral contraceptive use and HIV infection. Int J STD AIDS 1990; 1: 447–8.PubMedGoogle Scholar
  141. 141.
    Simonsen JN, Plummer FA, Ngugi EN et al. HIV infection among lower socioeconomic strata prostitutes in Nairobi. AIDS 1990; 4: 139–44.PubMedCrossRefGoogle Scholar
  142. 142.
    Darrow WW, CDC Collaborative Group. Human immunodeficiency virus type 1 and other sexually transmitted infections in American prostitutes. Am J Epidemiol, 1991 (in press).Google Scholar
  143. 143.
    Carael M, Van de Perre PH, Lepage PH et al. Human immunodeficiency virus transmission among heterosexual couples in Central Africa. AIDS 1988; 2: 201–5.PubMedCrossRefGoogle Scholar
  144. 144.
    Latif AS, Katzenstein DA, Bassett MT, Houston S, Emmanuel JC, Marowa E. Genital ulcers and transmission of HIV among couples in Zimbabwe. AIDS 1989; 3: 519–23.PubMedCrossRefGoogle Scholar
  145. 145.
    Siraprasiri T, Thanprasertsuk S, Rodklay A et al. Study of risk factors for HIV infection among prostitutes in Chiengmai, Thailand. Presented at Field Epidemiology Training Program Second International Conference, Puebla, Mexico, January 1990.Google Scholar
  146. 146.
    Mati J, Maggwa A, Chewe D et al. Contraceptive use and HIV infection among women attending family planning clinics in Nairobi. Sixth International Conference on AIDS, Abstract No. Th.C.99, San Francisco, June 24, 1990.Google Scholar
  147. 147.
    European Study Group. Risk factors for male to female transmission of HIV. Br Med J 1989; 298: 411–15.CrossRefGoogle Scholar
  148. 148.
    Musicco M, The Italian Partners’ Study. Oral contraception, IUD, condom use and man to woman sexual transmission of HIV infection. Sixth International Conference on AIDS, Abstract No. Th.C. 584, San Francisco, June 24, 1990.Google Scholar
  149. 149.
    Edelman DA. The use of intrauterine contraceptive devices, pelvic inflammatory disease, and Chlamydia trachomatis infection. Am J Obstet Gynecol 1988; 158: 956–9.PubMedGoogle Scholar
  150. 150.
    Daling JR, Department of Epidemiology, University of Washington, School of Public Health. Personal communication, March 28, 1991.Google Scholar
  151. 151.
    Kronmal RA, Whitney CW, Mumford SD. The intrauterine device and pelvic inflammatory disease: the Women’s Health Study reanalyzed. J Clin Epidemiol 1991; 44: 109–22.PubMedCrossRefGoogle Scholar
  152. 152.
    Burkman RT, Lee NC, Ory HW, Rubin GL. Response to “The intrauterine device and pelvic inflammatory disease: the Women’s Health Study reanalyzed. ” J Clin Epidemiol 1991; 44: 123–5.PubMedCrossRefGoogle Scholar
  153. 153.
    Senanayake P, Kramer DG. Contraception and the etiology of pelvic inflammatory disease: new perspectives. Am J Obstet Gynecol 1980; 138: 852–60.PubMedGoogle Scholar
  154. 154.
    Kahn JG, Walker CK, Washington AE, Landers DV, Sweet RL. Diagnosing pelvic inflammatory disease: a comprehensive analysis and new algorithm. JAMA, 1991 (in press).Google Scholar
  155. 155.
    Paavonen J, Vesterinen E. Intrauterine contraceptive device use in patients with acute salpingitis. Contraception 1980; 22: 107–14.PubMedCrossRefGoogle Scholar
  156. 156.
    Burkman RT, Women’s Health Study. Association between intrauterine device and pelvic inflammatory disease. Obstet Gynecol 1981; 57: 269–76.PubMedGoogle Scholar
  157. 157.
    Kaufman DW, Watson J, Rosenberg L et al. The effect of different types of intrauterine devices on the risk of pelvic inflammatory disease. JAMA 1983; 250: 759–62.PubMedCrossRefGoogle Scholar
  158. 158.
    Lee NC, Rubin GL, Ory HW, Burkman RT. Type of intrauterine device and the risk of pelvic inflammatory disease. Obstet Gynecol 1983; 62: 1–6.PubMedGoogle Scholar
  159. 159.
    Witoonpanich P, Koetsawang A, Koetsawang S et al. PID associated with fertility regulating agents. Contraception 1984; 30: 1–21.CrossRefGoogle Scholar
  160. 160.
    Vessey MP, Yeates D, Flavel R, McPherson K. Pelvic inflammatory disease and the intrauterine device: findings in a large cohort study. Br Med J 1981; 282: 855–7.CrossRefGoogle Scholar
  161. 161.
    Buchan H, Villard-Mackintosh L, Vessey M, Yeates D, McPherson K. Epidemiology of pelvic inflammatory disease in parous women with special reference to intrauterine device use. Br J Obstet Gynaecol 1990; 97: 780–88.PubMedCrossRefGoogle Scholar
  162. 162.
    Grimes DA. Intrauterine devices and pelvic inflammatory disease: recent developments. Contracept 1987; 36: 97–109.CrossRefGoogle Scholar
  163. 163.
    Sinei SKA, Schulz KF, Lamptey PR et al. Preventing IUD-related pelvic infection: the efficacy of prophylactic doxycycline at insertion. Br J Obstet Gynaecol 1990; 97: 412–9.PubMedCrossRefGoogle Scholar
  164. 164.
    Ladipo OA, Farr G, Otolorin E et al. Prevention of IUD-related pelvic infection: the efficacy of prophylactic doxycycline at IUD insertion. Adv Contracept 1991; 7: 43–54.PubMedCrossRefGoogle Scholar
  165. 165.
    Cramer DW, Schiff I, Schoenbaum SC et al. Tubal infertility and the intrauterine device. N Engl J Med 1985; 312: 941–7.PubMedCrossRefGoogle Scholar
  166. 166.
    Daling JR, Weiss NS, Metch DJ et al. Primary tubal infertility in relation to the use of an intrauterine device. N Engl J Med 1985; 312: 937–41.PubMedCrossRefGoogle Scholar
  167. 167.
    Falk HC. Interpretation of the pathogenesis of pelvic infection as determined by cornual resection. Am J Obstet Gynecol 1946; 52: 66–72.PubMedGoogle Scholar
  168. 168.
    Haji SN. Does sterilization prevent pelvic infection? J Reprod Med 1978; 20: 289–90.Google Scholar
  169. 169.
    Vessey M, Huggins G, Lawless M, Yeates D, McPherson K. Tubal sterilization: findings in a large prospective study. Br J Obstet Gynaecol 1983; 90: 203–9.PubMedCrossRefGoogle Scholar
  170. 170.
    Huggins GR, Sondheimer SJ. Complications of female sterilization: immediate and delayed. Fertil Steril 1984; 41: 337–55.PubMedGoogle Scholar
  171. 171.
    Vermesh M, Confino E, Boler LR, Friberg J, Gleicher N. Acute salpingitis in sterilized women. Obstet Gynecol 1987; 69: 265–7.PubMedGoogle Scholar
  172. 172.
    Edelman DA, Berger GS. Contraceptive practice and tuboovarian abscess. Am J Obstet Gynecol 1980; 138: 541–5.PubMedGoogle Scholar
  173. 173.
    Burkman RT, Tonascia JA, Atienza M, King TM. Untreated endocervical gonorrhea and endometritis following elective abortion. Am J Obstet Gynecol 1976; 126: 648–51.PubMedGoogle Scholar
  174. 174.
    Osser S, Persson K. Postabortal pelvic infection associated with Chlamydia trachomatis and the influence of humoral immunity. Am J Obstet Gynecol 1984; 150: 699–703.PubMedGoogle Scholar
  175. 175.
    Westergaard L, Philipsen T, Scheibel J. Significance of cervical Chlamydia trachomatis infection in postabortal pelvic inflammatory disease. Obstet Gynecol 1982; 60: 322–5.PubMedGoogle Scholar
  176. 176.
    Grimes DA, Schulz KF, Cates W Jr. Prophylactic antibiotics for curettage abortions. Am J Obstet Gynecol 1984; 150: 689–94.PubMedGoogle Scholar
  177. 177.
    Park TK, Flock M, Schulz KF, Grimes DA. Preventing febrile complications of suction curettage abortion. Am J Obstet Gynecol 1985; 152: 252–5.PubMedGoogle Scholar
  178. 178.
    Darj E, Stralm E-B, Nilsson S. The prophylactic effect of doxycycline on postoperative infection rate after first-trimester abortion. Obstet Gynecol 1987; 70: 755–8.PubMedGoogle Scholar
  179. 179.
    Qvigstad E, Skaug K, Jerve F, Vik ISS, Ulstrup JC. Therapeutic abortion and Chlamydia trachomatis infection. Br J Vener Dis 1982; 58: 182–3.PubMedGoogle Scholar
  180. 180.
    Osser S, Persson K. Postabortal pelvic infection associated with Chlamydia trachomatis and the influence of humoral immunity. Am J Obstet Gynecol 1984; 150: 699–703.PubMedGoogle Scholar
  181. 181.
    Barbacci MB, Spence MR, Kappus EW, Burkman RC, Rao L, Quinn TC. Postabortal endometritis and isolation of Chlamydia trachomatis. Obstet Gynecol 1986; 68: 686–90.PubMedGoogle Scholar
  182. 182.
    Heisterberg L, Möller BR, Manthorpe T, Sorensen S, Petersen K, Nielsen NC. Prophylaxis with lymecycline in induced first-trimester abortion: a clinical controlled trial assessing the role of Chlamydia trachomatis and Mycoplasma hominis. Sex Transm Dis 1985; 12: 782–5.Google Scholar
  183. 183.
    Schioötz H, Csango PA. A prospective study of Chlamydia trachomatis in first trimester abortion. Ann Clin Res 1985; 17: 60–3.Google Scholar
  184. 184.
    Giertz G, Kallings I, Nordenvall M, Fuchs T. A prospective study of Chlamydia trachomatis infection following legal abortion. Acta Obstet Gynecol Scand 1987; 66: 107–9.PubMedCrossRefGoogle Scholar
  185. 185.
    Liskin L. Complications of abortion in developing countries. Popul Rep 1980; F-7:1–32.Google Scholar
  186. 186.
    Coeytaux F. Induced abortion in Sub-Saharan Africa: what we do and do not know. Stud Fam Plann 1988; 19: 186–90.PubMedCrossRefGoogle Scholar
  187. 187.
    Sherris J. The impact of unsafe abortion in the developing world. Outlook 1989; 7 (3): 2–7.Google Scholar
  188. 188.
    Henshaw SK. Induced abortion: a world review, 1990. Fam Plann Perspect 1990; 22: 76–89.PubMedCrossRefGoogle Scholar
  189. 189.
    Moreno L, Goldman N. Contraceptive failure rates in developing countries: evidence from the Demographic and Health Surveys. Int Fam Plann Perspect 1991; 17: 44–9.CrossRefGoogle Scholar
  190. 190.
    Kestelman P, Trussell J. Efficacy of combined barrier contraceptives. Submitted to Fam Plann Perspect, 1991.Google Scholar
  191. 191.
    United Nations Family Planning Association. Levels and trends of contraceptive use as assessed in 1988, New York: United Nations, 1989.Google Scholar
  192. 192.
    Judson FN. Fear of AIDS and gonorrhea rates in homosexual men. Lancet 1983; 2: 159.PubMedCrossRefGoogle Scholar
  193. 193.
    Handsfield HH. Decreasing incidence of gonorrhea in homosexually active men-minimal effect on risk of AIDS. West J Med 1985; 143: 469–72.PubMedGoogle Scholar
  194. 194.
    Alter MJ, Hadler SC, Margolis HS et al. The changing epidemiology of hepatitis B in the United States. JAMA 1990; 263: 1218–22.PubMedCrossRefGoogle Scholar
  195. 195.
    Sorvillo FJ, Lieb L, Mascola L, Waterman SH. Declining rates of amebiasis in Los Angeles County. Am J Public Health 1989; 79: 1563–4.PubMedCrossRefGoogle Scholar
  196. 196.
    Bertrand JR, Makani B, Hassig SE et al. AIDS-related knowledge, sexual behavior and condom use among men and women in Kinshasa, Zaire. Am J Public Health 1991; 81: 53–8.PubMedCrossRefGoogle Scholar
  197. 197.
    Goldberg HI, Lee NC, Oberle MW, Peterson HB. Knowledge about condoms and their use in less developed countries during a period of rising AIDS prevalence. Bull WHO 1989; 67: 85–91.PubMedGoogle Scholar
  198. 198.
    Cates W Jr, Farley TMM, Rowe PJ, WHO Task Force on Infertility. Worldwide patterns of infertility: Is Africa different? Lancet 1985; 2: 596–8.CrossRefGoogle Scholar
  199. 199.
    WHO Task Force on Infertility (Cates W Jr, Farley TMM, Rowe PJ). Infections, pregnancies and infertility: perspectives on prevention. Fertil Steril 1987; 47: 964–8.Google Scholar
  200. 200.
    Bowen GS, Aral SO, Magder LS, Reed DS, Dratman C, Wasser S. Risk behaviors for HIV infection in clients of Pennsylvania family planning clinics. Fam Plann Perspect 1990; 22: 62–4.PubMedCrossRefGoogle Scholar
  201. 201.
    Upchurch DM, Farmer MY, Glasser D, Hook EW III. Contraceptive needs and practices among women attending an inner city STD clinic. Am J Public Health 1987; 77: 1427–30.PubMedCrossRefGoogle Scholar
  202. 202.
    Bureau of Community Health Services. Guidelines for health promotion and disease prevention services in reproductive health care settings, Washington, DC, and Rockville, Maryland, 1981.Google Scholar
  203. 203.
    Brown ST, Wiesner PJ. Problems and approaches to the control and surveillance of sexually transmitted agents associated with pelvic inflammatory disease in the United States. Am J Obstet Gynecol 1980; 138: 1096–1100.PubMedGoogle Scholar
  204. 204.
    Aral SO, Mosher WD, Horn MC, Cates W Jr. Screening for sexually transmitted diseases by family planning providers: is it adequate and appropriate? Fam Plann Perspect 1986; 18: 255–8.PubMedCrossRefGoogle Scholar
  205. 205.
    Schachter J, Stoner E, Moncada J. Screening for chlamydial infections in women attending family planning clinics-evaluation of presumptive indicators for therapy. West J Med 1983; 138: 375–9.PubMedGoogle Scholar
  206. 206.
    Addiss DG, Vaughn ML, Holzhueter MA, Bakken LL, Davis JP. Selective screening for Chlamydia trachomatis infection in nonurban family planning clinics in Wisconsin. Fam Plann Perspect 1987; 19: 252–6.PubMedCrossRefGoogle Scholar
  207. 207.
    Bagshaw SN, Edwards D. Risk factors for Chlamydia trachomatis infection of the cervix: a prospective study of 2,000 patients at a family planning clinic. N Z Med J 1987; 100: 401–3.PubMedGoogle Scholar
  208. 208.
    Binns B, Williams T, McDowell J, Brunham RC. Screening for Chlamydia trachomatis infection in a pregnancy counseling clinic. Am J Obstet Gynecol 1988; 159: 1144–9.PubMedGoogle Scholar
  209. 209.
    Begley CE, McGill L, Smith PB. The incremental cost of screening, diagnosis, and treatment of gonorrhea and chlamydia in a family planning clinic. Sex Transm Dis 1989; 16: 63–7.PubMedCrossRefGoogle Scholar
  210. 210.
    Stein ZA. The need for methods women can use. Am J Public Health 1990; 80: 460–2.PubMedCrossRefGoogle Scholar
  211. 211.
    Aral SO, Cates W Jr, Beral V. Are sexually transmitted diseases (STD) inherently sexist? Gender as a risk factor in STD epidemiology. In: Blumenthal S, Eichler A, Weissman G, eds. Women and AIDS, Washington, DC: American Psychological Press (in press).Google Scholar
  212. 212.
    World Health Organization. AIDS prevention: guidelines for MCH/FP programme managers. I. AIDS and family planning. Geneva, 1990: 29–38.Google Scholar
  213. 213.
    Wasserheit JN. Epidemiological synergy. Interrelationships between HIV infection and other STDs. Presented at the International Workshop on AIDS and Reproductive Health, Bellagio, Italy, October 29, 1990. To be published by Plenum Press in AIDS and Women’s Health.Google Scholar
  214. 214.
    Bayer R. AIDS and the future of reproductive freedom. Milbank Quart 1990; 8 (Suppi 2): 179–204.CrossRefGoogle Scholar
  215. 215.
    Levine C, Dubler NN. HIV and childbearing: 1) Uncertain risks and bitter realities: the reproductive choices of HIV-infected women. Milbank Quart 1990; 68: 321–51.CrossRefGoogle Scholar
  216. 216.
    Arras JD. HIV and childbearing: 2) AIDS and reproductive decisions: having children in fear and trembling. Milbank Quart 1990; 68: 353–82.CrossRefGoogle Scholar
  217. 217.
    Holmes KK, Karon JM, Kreiss J. The increasing frequency of heterosexually acquired Aids in the United States, 1983–1988. Am J Public Health 1990; 80: 858–62.PubMedCrossRefGoogle Scholar
  218. 218.
    Donovan P. AIDS and family planning clinics: confronting the crisis. Fam Plann Perspect 1987; 19: 111–38.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1992

Authors and Affiliations

  • Willard Cates
    • 1
    • 3
  • Katherine M. Stone
    • 2
    • 3
  1. 1.Division of TrainingEpidemiology Program OfficeUSA
  2. 2.Clinical Research Investigator Division of STD/HIV PreventionUSA
  3. 3.Centers for Disease ControlAtlantaUSA

Personalised recommendations